Načítá se...
The JAK2 V617F somatic mutation, mortality and cancer risk in the general population
JAK2 V617F is present in the majority of patients with myeloproliferative cancer; however, its prevalence and clinical significance in the general population is unknown. We screened for presence of the mutation in 10,507 participants from the Copenhagen City Heart Study with up to 17.6 years of foll...
Uloženo v:
| Hlavní autoři: | , , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Ferrata Storti Foundation
2011
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3046277/ https://ncbi.nlm.nih.gov/pubmed/21160067 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2010.033191 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|